Evidence map›Paper›PMID 36903629›Full record

ArticleMolecules (Basel, Switzerland)2023

In Silico Exploration of Microtubule Agent Griseofulvin and Its Derivatives Interactions with Different Human β-Tubulin Isotypes.

Parisa Aris, Masoud Mohamadzadeh, Alibek Kruglikov, Mahbubeh Askari Rad, Xuhua Xia

Full text read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Parisa ArisDepartment of Biology, University of Ottawa, 30 Marie Curie, Station A, P.O. Box 450, Ottawa, ON K1N 6N5, Canada.ORCID 0000-0003-2774-7035
Masoud MohamadzadehDepartment of Chemistry, Faculty of Sciences, University of Hormozgan, Bandar Abbas 71961, Iran.ORCID 0000-0002-5054-5602
Alibek KruglikovDepartment of Biology, University of Ottawa, 30 Marie Curie, Station A, P.O. Box 450, Ottawa, ON K1N 6N5, Canada.ORCID 0000-0001-6074-8764
Mahbubeh Askari RadDepartment of Biology, University of Ottawa, 30 Marie Curie, Station A, P.O. Box 450, Ottawa, ON K1N 6N5, Canada.
Xuhua XiaDepartment of Biology, University of Ottawa, 30 Marie Curie, Station A, P.O. Box 450, Ottawa, ON K1N 6N5, Canada.ORCID 0000-0002-3092-7566

Funding

Natural Sciences and Engineering Research Council RGPIN/2018-03878
6 · The paper itself

Abstract

Tubulin isotypes are known to regulate microtubule stability and dynamics, as well as to play a role in the development of resistance to microtubule-targeted cancer drugs. Griseofulvin is known to disrupt cell microtubule dynamics and cause cell death in cancer cells through binding to tubulin protein at the taxol site. However, the detailed binding mode involved molecular interactions, and binding affinities with different human β-tubulin isotypes are not well understood. Here, the binding affinities of human β-tubulin isotypes with griseofulvin and its derivatives were investigated using molecular docking, molecular dynamics simulation, and binding energy calculations. Multiple sequence analysis shows that the amino acid sequences are different in the griseofulvin binding pocket of βI isotypes. However, no differences were observed at the griseofulvin binding pocket of other β-tubulin isotypes. Our molecular docking results show the favorable interaction and significant affinity of griseofulvin and its derivatives toward human β-tubulin isotypes. Further, molecular dynamics simulation results show the structural stability of most β-tubulin isotypes upon binding to the G1 derivative. Taxol is an effective drug in breast cancer, but resistance to it is known. Modern anticancer treatments use a combination of multiple drugs to alleviate the problem of cancer cells resistance to chemotherapy. Our study provides a significant understanding of the involved molecular interactions of griseofulvin and its derivatives with β-tubulin isotypes, which may help to design potent griseofulvin analogues for specific tubulin isotypes in multidrug-resistance cancer cells in future.

Indexed as

GriseofulvinTubulinBinding SitesHumansMicrotubulesMolecular Docking SimulationPaclitaxelGriseofulvinPaclitaxelTubulincancerdockinggriseofulvingriseofulvin derivativesmolecular dynamicsβ-tubulin isotypes

Identifiers

PMID36903629
PMCPMC10005519

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read7
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.